Prognostic Value of Telomeric Zinc Finger-Associated Protein Expression in Adenocarcinoma and Squamous Cell Carcinoma of Lung

<i>Background and Objectives</i>: Telomeric zinc finger-associated protein (TZAP) is a telomere regulation protein, previously known as ZBTB48. It binds preferentially to elongated telomeres, competing with telomeric repeat factors 1 and 2. TZAP expression may be associated with carcinog...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gun-Jik Kim, Jae-Ho Lee, Mincheol Chae, Deok-Heon Lee
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/37cad0281be44653b190723e1ec114e2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:<i>Background and Objectives</i>: Telomeric zinc finger-associated protein (TZAP) is a telomere regulation protein, previously known as ZBTB48. It binds preferentially to elongated telomeres, competing with telomeric repeat factors 1 and 2. TZAP expression may be associated with carcinogenesis, however; this study has not yet been performed in lung cancer. In this study, we examined the clinicopathological and prognostic values of TZAP expression in non-small cell lung cancer (NSCLC). <i>Materials and Methods:</i> Data were collected from The Cancer Genome Atlas. The clinical and prognostic values of TZAP for NSCLC were examined in adenocarcinoma (AD) and squamous cell carcinoma (SCC). <i>Results:</i> TZAP expression significantly increased in NSCLC tissues compared with normal tissues. In AD, TZAP expression was lower in patients with higher T stage (<i>p</i> = 0.005), and was associated with lymph node stage in SCC (<i>p</i> = 0.005). Survival analysis showed shorter disease-free survival in AD patients with lower TZAP expression (<i>p</i> = 0.047). TZAP expression did not have other clinical or prognostic value for AD and SCC. <i>Conclusions</i>: TZAP expression is a potential prognostic marker for NSCLC, especially in patients with AD.